drugset / Trial / NCT07671534
Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is an open label phase II study using metronomic low-dose gemcitabine and mitomycin c given intravenously, and thalidomide administered orally, for patients with advanced solid tumors.
Timeline
- Start
- 2026-06
- Primary completion
- 2029-06
- Completion
- 2029-06
Publications
- Background Shen Y, Li S, Wang X, Wang M, Tian Q, Yang J, Wang J, Wang B, Liu P, Yang J. Tumor vasculature remolding by thalidomide increases delivery and efficacy of cisplatin. J Exp Clin Cancer Res. 2019 Oct 28;38(1):427. doi: 10.1186/s13046-019-1366-x.
- Background Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282 (Jun 1958)):457-81.
- Background Isacoff W.H., Chawla NS, Sekhon S, Bhuiyan I, Monick E, Jeffrey S, Gordon EM. Treatment of Elderly Patients with Advanced Pancreatic Ductal Adenocarcinoma Utilizing a Metronomic Dose and Schedule of Chemotherapy: A Better Approach. Cancers 2025 Preprint doi:10.20944/preprints202510.0364.v1
- Background Isacoff WH, Cooper B, Bartlett A, McCarthy B, Yu KH. ChemoSensitivity Assay Guided Metronomic Chemotherapy Is Safe and Effective for Treating Advanced Pancreatic Cancer. Cancers (Basel). 2022 Jun 13;14(12):2906. doi: 10.3390/cancers14122906.
- Background Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
- Background Liu Q, Chiang ZC, Zhao X, Cui D, Li X, Chen H, Lin F, Jiang T, Chen Q, Lin X, Lin J. Strengthening Effect of Thalidomide Combined with an Anti-PD1 Antibody on Enhancing Immunity for Lung Cancer Therapy. Curr Pharm Biotechnol. 2025;26(17):2724-2737. doi: 10.2174/0113892010319495241218114812.
- Background Chen H, Wu S, Tang M, Zhao R, Zhang Q, Dai Z, Gao Y, Yang S, Li Z, Du Y, Yang A, Zhong L, Lu L, Xu L, Shen X, Liu S, Zhong J, Li X, Lu H, Xiong H, Shen Y, Chen H, Gong S, Xue H, Ge Z. Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia. N Engl J Med. 2023 Nov 2;389(18):1649-1659. doi: 10.1056/NEJMoa2303706.
- Background Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38:29-41.
- Background Ballon J, Savage PA, Agarwal AD, Jeffrey S, Syed S, et al. A Phase 2 Study Using Metronomic Gemcitabine, Doxorubicin, and Docetaxel Plus Nivolumab Advanced Leiomyosarcoma and Liposarcoma (NCT04535713). J Clin 1ncol 1515, 2025
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 600 mg/m2 | Intravenous |
| Subject | Mitomycin C | Other / unclassified | 14 mg | Intravenous |
| Subject | Thalidomide | Other / unclassified | 100 mg | Oral |
Indications
No indication recorded.